Sustained efficacy of eszopiclone over 6 months of nightly treatment: Results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia

Sleep

Volumn 26, Issue 7, 2003, Pages 793-799

  Krystal, Andrew D ^a   Walsh, James K ^b   Laska, Eugene ^c,d   Caron, Judy ^e   Amato, David A ^e   Wessel, Thomas C ^e   Roth, Thomas ^f  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e SUNOVION PHARMACEUTICALS INC   (United States)

^f HENRY FORD HOSPITAL   (United States)

Author keywords

Awakenings; Chronic insomnia; Eszopiclone; Long term; Next day function; Non benzodiazepine; Sleep; Sleep initiation and maintenance disorders; Tolerance; Wakefulness after sleep onset

Indexed keywords

ESZOPICLONE; PLACEBO; HYPNOTIC SEDATIVE AGENT; PIPERAZINE DERIVATIVE; ZOPICLONE;

ADULT; AGED; ALERTNESS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; HEADACHE; HUMAN; INSOMNIA; LONG TERM CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP PATTERN; SLEEP TIME; TASTE AVERSION; UNPLEASANT SENSATION; WELLBEING; CHRONIC DISEASE; CIRCADIAN RHYTHM; DRUG EFFECT; FEMALE; MALE; MIDDLE AGED; TIME; WAKEFULNESS;

ADULT; AGED; CHRONIC DISEASE; CIRCADIAN RHYTHM; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; PIPERAZINES; SLEEP INITIATION AND MAINTENANCE DISORDERS; TIME FACTORS; WAKEFULNESS;

EID: 1842463058     PISSN: 01618105     EISSN: None     Source Type: Journal    
DOI: 10.1093/sleep/26.7.793     Document Type: Article

References (24)

1. Balter MB, Uhlenhuth EH. New epidemiologic findings about insomnia and its treatment. J Clin Psychiatry 1992;53 Suppl:34-9
2. Nowell PD, Mazumdar S, Buysse DJ, Dew MA, Reynolds CF, III, Kupfer DJ. Benzodiazepines and zolpidem for chronic insomnia. a meta-analysis of treatment efficacy. JAMA 1997;278 2170-7
3. Scharf MB, Roth T, Vogel GW, Walsh JK. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 1994;55:192-9
4. Walsh JK, Pollak CP, Scharf MB, Schweitzer PK, Vogel GW Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia. Clin Neuropharmacol 2000;23:17-21.
5. Morin CM, Colecchi C, Stone J, Sood R, Brink D Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA 1999;281:991-9.
6. Mendelson WB, Roth T, Cassella J, et al. The treatment of chronic insomnia: drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation Unit (NCDEU) meeting symposium. Sleep Med Rev 2003. In press.
7. Roehrs T, Pedrosi B, Rosenthal L, Roth T Hypnotic self administration and dose escalation. Psychopharmacology (Berl) 1996;127:150-4.
8. Buysse DJ, Reynolds CF, III, Kupfer DJ, et al. Clinical diagnoses in 216 insomnia patients using the International Classification of Sleep Disorders (ICSD), DSM-IV and ICD-10 categories: a report from the APA/NIMH DSM-IV Field Trial. Sleep 1994;17:630-7.
9. Ohayon M. Epidemiological study of insomnia in the general population. Sleep 1996;19:S7-15
10. Vgontzas AN, Bixler EO, Lin HM, et al. Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis. clinical implications. J Clin Endocrinol Metab 2001;86:3787-94.
11. Asnis GM, Chakraburtty A, DuBoff EA, et al. Zolpidem in SSRI-treated patients with persistent insomnia J Clin Psychiatry 1999;60:668-76
12. Fernandez C, Maradeix V, Gimenez F, Thuillier A, Farinotti R. Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. Drug Metab Dispos 1993;21:1125-8
13. Carlson JN, Haskew R, Wacker J, Maisonneuve IM, Glick SD, Jerussi TP. Sedative and anxiolytic effects of zopiclone's enantiomers and metabolite. Eur J Pharmacol 2001;415:181-9.
14. Fernandez C, Alet P, Davrinche C, et al Stereoselective distribution and stereoconversion of zopiclone enantiomers in plasma and brain tissues in rats J Pharm Pharmacol 2002;54:335-40.
15. Leese P, Maier G. Eszopiclone: Pharmacokinetic (PK) and pharmacodynamic (PD) effects of a novel anti-insomnia agent after daytime administration in healthy subjects. Sleep 2002;25:A45
16. Rosenberg RP, Jamieson A, Vaickus L, Roth T. Eszopiclone, a novel non-benzodiazepine sedative-hypnotic. efficacy and safety in a model of transient insomnia. Sleep 2002,25 A68-9
17. Zammit G, Gillin JC, McNabb L, Caron J, Roth T Eszopiclone, a novel non-benzodiazepine anti-insomnia agents: a six-week efficacy and safety study in adult patients with chronic insomnia Sleep 2003;26:A297.
18. Hohagen F, Kappler C, Schramm E, Riemann D, Weyerer S, Berger M Sleep onset insomnia, sleep maintaining insomnia and insomnia with early morning awakening-temporal stability of subtypes in a longitudinal study on general practice attenders. Sleep 1994;17:551-4
19. th ed. Washington, DC: American Psychiatric Publishing, Inc, 2000.
20. Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ Computer-administered clinical rating scales A review. Psychopharmacology (Berl) 1996;127:291-301.
21. Ohayon MM, Caulet M, Arbus L, et al Are prescribed medications effective in the treatment of insomnia complaints? J Psychosom Res 1999;47:359-68
22. Oswald I, French C, Adam K, Gilham J. Benzodiazepine hypnotics remain effective for 24 weeks. Br Med J (Clin Res Ed) 1982;284:860-3
23. Fleming JA, Bourgouin J, Hamilton P A sleep laboratory evaluation of the long-term efficacy of zopiclone. Can J Psychiatry 1988;33:103-7.
24. Fillingim JM. Double-blind evaluation of the efficacy and safety of temazepam in out-patients with insomnia Br J Clin Pharmacol 1979;8:73S-7